Pathological and molecular mechanisms underlying resistance to recombinant human erythropoietin therapy in the remnant kidney rat model of chronic kidney disease associated anemia

Biochimie

Volumn 125, Issue , 2016, Pages 150-162

  Ribeiro, Sandra ^a   Garrido, Patrícia ^b   Fernandes, João ^b   Vala, Helena ^c   Rocha Pereira, Petronila ^d   Costa, Elísio ^a   Belo, Luís ^a   Reis, Flávio ^b   Santos Silva, Alice ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c POLYTECHNIC INSTITUTE OF VISEU   (Portugal)

^d UNIVERSITY OF BEIRA INTERIOR   (Portugal)

Author keywords

Anemia; CTGF; Erythropoietin; Hyporesponsiveness; Inflammation; TGF 1

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; RECOMBINANT ERYTHROPOIETIN; TRANSFORMING GROWTH FACTOR BETA1; CYTOKINE; EPO PROTEIN, HUMAN; ERYTHROPOIETIN; RECOMBINANT PROTEIN;

ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE ASSOCIATION; HEMATOLOGY; HYPOXIA; IRON METABOLISM; KIDNEY; KIDNEY FIBROSIS; MALE; MOLECULAR MECHANICS; NEPHRECTOMY; NONHUMAN; RAT; SHAM PROCEDURE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; ANIMAL; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; DRUG RESISTANCE; HUMAN; METABOLISM; PATHOLOGY; RENAL INSUFFICIENCY, CHRONIC; WISTAR RAT;

ANEMIA; ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; DRUG RESISTANCE; ERYTHROPOIETIN; HUMANS; MALE; RATS; RATS, WISTAR; RECOMBINANT PROTEINS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84964388884     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2016.03.012     Document Type: Article

References (50)

1. B.C. Astor, P. Muntner, A. Levin, J.A. Eustace, and J. Coresh Association of kidney function with anemia: the third national health and nutrition examination survey (1988-1994) Arch. Intern. Med. 162 2002 1401 1408
2. F. Locatelli, R.L. Pisoni, C. Combe, J. Bommer, V.E. Andreucci, L. Piera, R. Greenwood, H.I. Feldman, F.K. Port, and P.J. Held Anaemia in haemodialysis patients of five european countries: association with morbidity and mortality in the dialysis outcomes and practice patterns study (dopps) Nephrol. Dial. Transpl. 19 2004 121 132
3. B.M. Robinson, M.M. Joffe, J.S. Berns, R.L. Pisoni, F.K. Port, and H.I. Feldman Anemia and mortality in hemodialysis patients: accounting for morbidity and treatment variables updated over time Kidney Int. 68 2005 2323 2330
4. S. Iimori, S. Naito, Y. Noda, H. Nishida, H. Kihira, N. Yui, T. Okado, S. Sasaki, S. Uchida, and T. Rai Anaemia management and mortality risk in newly visiting patients with chronic kidney disease in japan: the ckd-route study Nephrology (Carlton) 20 2015 601 608
5. M. Nangaku, and K.U. Eckardt Pathogenesis of renal anemia Semin. Nephrol. 26 2006 261 268
6. C. Lacombe, and P. Mayeux Biology of erythropoietin Haematologica 83 1998 724 732
7. V.H. Haase Regulation of erythropoiesis by hypoxia-inducible factors Blood Rev. 27 2013 41 53
8. I. Loeffler, and G. Wolf The role of hypoxia and morg1 in renal injury Eur. J. Clin. Investig. 45 2015 294 302
9. K.S. Hodgkins, and H.W. Schnaper Tubulointerstitial injury and the progression of chronic kidney disease Pediatr. Nephrol. 27 2012 901 909
10. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group KDIGO clinical practice guideline for anemia in chronic kidney disease Kidney Int. Suppl. 2 2012 279 335
11. M.O. Arcasoy The non-haematopoietic biological effects of erythropoietin Br. J. Haematol. 141 2008 14 31
12. KDOQI & National Kidney Foundation KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease Am. J. Kidney Dis. 47 2006 S11 S145
13. R.D. Kilpatrick, C.W. Critchlow, S. Fishbane, A. Besarab, C. Stehman-Breen, M. Krishnan, and B.D. Bradbury Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients Clin. J. Am. Soc. Nephrol. 3 2008 1077 1083
14. V. Panichi, A. Rosati, R. Bigazzi, S. Paoletti, E. Mantuano, S. Beati, V. Marchetti, G. Bernabini, G. Grazi, G.M. Rizza, M. Migliori, R. Giusti, A. Lippi, A. Casani, G. Barsotti, and C. Tetta Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: results from the riscavid study Nephrol. Dial. Transpl. 26 2011 2641 2648
15. M. do Sameiro-Faria, S. Ribeiro, E. Costa, D. Mendonca, L. Teixeira, P. Rocha-Pereira, J. Fernandes, H. Nascimento, M. Kohlova, F. Reis, L. Amado, E. Bronze-da-Rocha, V. Miranda, A. Quintanilha, L. Belo, and A. Santos-Silva Risk factors for mortality in hemodialysis patients: two-year follow-up study Dis. Markers 35 2013 791 798
16. D.W. Johnson, C.A. Pollock, and I.C. Macdougall Erythropoiesis-stimulating agent hyporesponsiveness Nephrology (Carlton) 12 2007 321 330
17. E. Costa, M. Lima, J.M. Alves, S. Rocha, P. Rocha-Pereira, E. Castro, V. Miranda, S.F. do, A. Loureiro, A. Quintanilha, L. Belo, and A. Santos-Silva Inflammation, t-cell phenotype, and inflammatory cytokines in chronic kidney disease patients under hemodialysis and its relationship to resistance to recombinant human erythropoietin therapy J. Clin. Immunol. 28 2008 268 275
18. E. Nemeth, S. Rivera, V. Gabayan, C. Keller, S. Taudorf, B.K. Pedersen, and T. Ganz Il-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin J. Clin. Investig. 113 2004 1271 1276
19. T. Ganz, and E. Nemeth Hepcidin and iron homeostasis Biochim. Biophys. Acta 1823 2012 1434 1443
20. E. Nemeth, M.S. Tuttle, J. Powelson, M.B. Vaughn, A. Donovan, D.M. Ward, T. Ganz, and J. Kaplan Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization Science 306 2004 2090 2093
21. A.E. Gaweda, L.J. Goldsmith, M.E. Brier, and G.R. Aronoff Iron, inflammation, dialysis adequacy, nutritional status, and hyperparathyroidism modify erythropoietic response Clin. J. Am. Soc. Nephrol. 5 2010 576 581
22. R.S. Hillman, and C.A. Finch Red Cell Manual fifth ed. 1985 Davis Company Philadephia
23. P. Garrido, S. Ribeiro, J. Fernandes, H. Vala, E. Bronze-da-Rocha, P. Rocha-Pereira, L. Belo, E. Costa, A. Santos-Silva, and F. Reis Iron-hepcidin dysmetabolism, anemia and renal hypoxia, inflammation and fibrosis in the remnant kidney rat model PLoS One 10 2015 e0124048
24. C.C. Tan, K.U. Eckardt, and P.J. Ratcliffe Organ distribution of erythropoietin messenger rna in normal and uremic rats Kidney Int. 40 1991 69 76
25. Y.A. Minamishima, and W.G. Kaelin Jr. Reactivation of hepatic epo synthesis in mice after phd loss Science 329 2010 407
26. T. Fehr, P. Ammann, D. Garzoni, W. Korte, W. Fierz, H. Rickli, and R.P. Wuthrich Interpretation of erythropoietin levels in patients with various degrees of renal insufficiency and anemia Kidney Int. 66 2004 1206 1211
27. F. Artunc, and T. Risler Serum erythropoietin concentrations and responses to anaemia in patients with or without chronic kidney disease Nephrol. Dial. Transpl. 22 2007 2900 2908
28. P.P. Kapitsinou, Q. Liu, T.L. Unger, J. Rha, O. Davidoff, B. Keith, J.A. Epstein, S.L. Moores, C.L. Erickson-Miller, and V.H. Haase Hepatic hif-2 regulates erythropoietic responses to hypoxia in renal anemia Blood 116 2010 3039 3048
29. B. Nath, and G. Szabo Hypoxia and hypoxia inducible factors: diverse roles in liver diseases Hepatology 55 2012 622 633
30. P. Garrido, S. Ribeiro, J. Fernandes, H. Vala, P. Rocha-Pereira, E. Bronze-da-Rocha, L. Belo, E. Costa, A. Santos-Silva, and F. Reis Resistance to recombinant human erythropoietin therapy in a rat model of chronic kidney disease associated anemia Int. J. Mol. Sci. 17 2015 E28
31. I.A. Gillespie, I.C. Macdougall, S. Richards, V. Jones, D. Marcelli, M. Froissart, and K.U. Eckardt Factors precipitating erythropoiesis-stimulating agent responsiveness in a european haemodialysis cohort: case-crossover study Pharmacoepidemiol. Drug Saf. 24 2015 414 426
32. M.B. Rivara, T.A. Ikizler, C.D. Ellis, R. Mehrotra, and J. Himmelfarb Association of plasma f2-isoprostanes and isofurans concentrations with erythropoiesis-stimulating agent resistance in maintenance hemodialysis patients BMC Nephrol. 16 2015 79
33. I.C. Macdougall, and A.C. Cooper Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines Nephrol. Dial. Transpl. 17 Suppl. 11 2002 39 43
34. M. Kimachi, S. Fukuma, S. Yamazaki, Y. Yamamoto, T. Akizawa, T. Akiba, A. Saito, and S. Fukuhara Minor elevation in c-reactive protein levels predicts incidence of erythropoiesis-stimulating agent hyporesponsiveness among hemodialysis patients Nephron 131 2 2015 123 130
35. S. Frede, J. Fandrey, H. Pagel, T. Hellwig, and W. Jelkmann Erythropoietin gene expression is suppressed after lipopolysaccharide or interleukin-1 beta injections in rats Am. J. Physiol. 273 1997 R1067 R1071
36. K. La Ferla, C. Reimann, W. Jelkmann, and T. Hellwig-Burgel Inhibition of erythropoietin gene expression signaling involves the transcription factors gata-2 and nf-kappab FASEB J. 16 2002 1811 1813
37. A. Kruse, D.E. Uehlinger, F. Gotch, P. Kotanko, and N.W. Levin Red blood cell lifespan, erythropoiesis and hemoglobin control Contrib. Nephrol. 161 2008 247 254
38. M. Nangaku, I. Mimura, J. Yamaguchi, Y. Higashijima, T. Wada, and T. Tanaka Role of uremic toxins in erythropoiesis-stimulating agent resistance in chronic kidney disease and dialysis patients J. Ren. Nutr. 25 2015 160 163
39. C.K. Chiang, T. Tanaka, and M. Nangaku Dysregulated oxygen metabolism of the kidney by uremic toxins: review J. Ren. Nutr. 22 2012 77 80
40. E. Costa, D.W. Swinkels, C.M. Laarakkers, P. Rocha-Pereira, S. Rocha, F. Reis, F. Teixeira, V. Miranda, M. do Sameiro Faria, A. Loureiro, A. Quintanilha, L. Belo, and A. Santos-Silva Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in haemodialysis patients Acta Haematol. 122 2009 226 229
41. J.P. Pinto, S. Ribeiro, H. Pontes, S. Thowfeequ, D. Tosh, F. Carvalho, and G. Porto Erythropoietin mediates hepcidin expression in hepatocytes through epor signaling and regulation of c/ebpalpha Blood 111 2008 5727 5733
42. G.J. Anderson, D.M. Frazer, and G.D. McLaren Iron absorption and metabolism Curr. Opin. Gastroenterol. 25 2009 129 135
43. V.H. Haase Hypoxia-inducible factor signaling in the development of kidney fibrosis Fibrogenes. Tissue Repair 5 2012 S16
44. H. Okada, T. Kikuta, T. Kobayashi, T. Inoue, Y. Kanno, M. Takigawa, T. Sugaya, J.B. Kopp, and H. Suzuki Connective tissue growth factor expressed in tubular epithelium plays a pivotal role in renal fibrogenesis J. Am. Soc. Nephrol. 16 2005 133 143
45. M.K. Phanish, S.K. Winn, and M.E. Dockrell Connective tissue growth factor-(ctgf, ccn2)-a marker, mediator and therapeutic target for renal fibrosis Nephron Exp. Nephrol. 114 2010 e83 92
46. F.J. Lopez-Hernandez, and J.M. Lopez-Novoa Role of tgf-beta in chronic kidney disease: an integration of tubular, glomerular and vascular effects Cell Tissue Res. 347 2012 141 154
47. V.H. Haase Inflammation and hypoxia in the kidney: friends or foes? Kidney Int. 88 2015 213 215
48. X. Yu, Y. Fang, X. Ding, H. Liu, J. Zhu, J. Zou, X. Xu, and Y. Zhong Transient hypoxia-inducible factor activation in rat renal ablation and reduced fibrosis with l-mimosine Nephrology (Carlton) 17 2012 58 67
49. M. Brines, N.S. Patel, P. Villa, C. Brines, T. Mennini, M. De Paola, Z. Erbayraktar, S. Erbayraktar, B. Sepodes, C. Thiemermann, P. Ghezzi, M. Yamin, C.C. Hand, Q.W. Xie, T. Coleman, and A. Cerami Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin Proc. Natl. Acad. Sci. U. S. A. 105 2008 10925 10930
50. W. Kriz, and M. LeHir Pathways to nephron loss starting from glomerular diseases-insights from animal models Kidney Int. 67 2005 404 419